MERSANA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.24 USD | +2.53% |
|
+0.16% | +38.58% |
| 20/03 | North American Morning Briefing : Markets on Hold -2- | DJ |
| 19/03 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
Chart calendar Mersana Therapeutics, Inc.
8aae07fa56d00.jD18v-qkR1cwcgZxfMo1Wg6aLXoL5WGzwI66xYnDthw.42UK_pjALzpmClc4T6d2KW_WZi1a1RbgmNzyhO2z8indECn2hOVxZAkiZQ~5da1a3262b1c51d9d88742561f1ff763
Upcoming events on Mersana Therapeutics, Inc.
Past events on Mersana Therapeutics, Inc.
| 12/03/2024 06:10 pm | Leerink Partners Global Biopharma Conference |
| 05/03/2024 07:40 pm | TD Cowen Health Care Conference |
| 28/02/2024 06:30 pm | Q4 2023 Earnings Call |
| 28/02/2024 05:30 pm | Q4 2023 Earnings Release |
| 08/02/2024 10:00 pm | Guggenheim Healthcare Talks Biotechnology Conference - Fireside Chat |
| 12/01/2024 12:45 am | JPMorgan Healthcare Conference |
| 07/11/2023 06:30 pm | Q3 2023 Earnings Call |
| 07/11/2023 05:30 pm | Q3 2023 Earnings Release |
| 08/08/2023 05:30 pm | Q2 2023 Earnings Release |
| 27/07/2023 05:30 pm | Business Update Call |
| 08/06/2023 07:30 pm | Annual General Meeting |
| 07/06/2023 06:30 pm | Jefferies Global Healthcare Conference |
| 05/06/2023 11:45 pm | American Society of Clinical Oncology Conference - Abstract Number: TPS5613 |
| 05/06/2023 11:45 pm | American Society of Clinical Oncology Conference - Abstract Number: TPS5614 |
| 05/06/2023 11:45 pm | American Society of Clinical Oncology Conference - Abstract Number: 5545 |
| 03/06/2023 06:30 pm | American Society of Clinical Oncology Conference - Abstract Number: TPS3154 |
| 31/05/2023 07:30 pm | TD Cowen Oncology Innovation Summit |
| 10/05/2023 09:50 pm | Bank of America Securities Healthcare Conference |
| 09/05/2023 05:30 pm | Q1 2023 Earnings Call |
| 09/05/2023 04:30 pm | Q1 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 42,1 42,4 -0.69% | 0,83 1,02 -18.95% | 0,04 0,03 30.3% | 26,6 24,7 7.4% | 36,9 40,9 -9.9% | 39,1 |
|
EBITDA Million USD | Released Forecast Spread | -29,0 -30,9 6.2% | -87,1 -81,0 -7.53% | -168 -166 -1.21% | -203 -194 -4.31% | -169 -175 3.34% | -92,2 |
|
EBIT Million USD | Released Forecast Spread | -30,2 -31,9 5.33% | -88,1 -81,8 -7.66% | -169 -169 0.09% | -204 -207 1.6% | -171 -177 3.21% | -89,1 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -28,2 -29,9 5.64% | -88,0 -81,5 -8.03% | -170 -169 -0.52% | -204 -208 1.64% | -172 -170 -0.77% | -86,9 |
|
Net income Million USD | Released Forecast Spread | -28,2 -29,9 5.78% | -88,0 -81,5 -7.98% | -170 -169 -0.67% | -204 -204 -0.27% | -172 -171 -0.61% | -83,7 |
|
EPS USD | Released Forecast Spread | -0,65 -0,63 -2.5% | -1,43 -1,33 -7.52% | -2,41 -2,40 -0.53% | -2,18 -2,21 1.41% | -1,48 -1,48 -0.18% | -0,66 |
| Announcement Date | 28/02/20 | 26/02/21 | 28/02/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,01 0,00 133.55% | 2,04 17,2 -88.19% | 4,28 2,20 94.55% | 5,57 56,8 -90.19% | 14,7 13,7 7.44% | 7,80 18,3 -57.33% | 10,7 13,0 -17.76% | 7,70 9,34 -17.62% | 10,7 14,8 -27.56% | 8,50 | 8,71 | 8,88 | 9,09 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -47,8 -46,0 -3.96% | -46,3 -7,00 -562.1% | -51,5 -44,0 -17.1% | -59,4 -42,0 -41.49% | -45,5 -43,0 -5.92% | -57,5 -55,0 -4.51% | -56,2 -59,0 4.78% | -20,5 -26,3 22.26% | -20,5 | -22,1 | -23,9 | -25,7 | ||
|
EBIT Million USD | Released Forecast Spread | -48,0 -48,1 0.18% | -46,6 -34,9 -33.43% | -51,8 -47,4 -9.17% | -59,6 10,3 -677.33% | -45,8 -52,1 12.03% | -57,8 -45,3 -27.57% | -56,5 -50,1 -12.72% | -35,7 -43,1 17.07% | -20,9 -21,4 2.3% | -23,2 | -23,9 | -24,6 | -25,4 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -49,0 -48,1 -1.81% | -47,3 -28,5 -66.08% | -52,2 -47,7 -9.49% | -59,8 9,76 -712.63% | -44,9 -52,6 14.51% | -56,2 -45,0 -24.83% | -54,3 -49,5 -9.67% | -41,7 -42,5 1.93% | -19,5 -19,6 0.35% | -23,5 | -23,9 | -24,5 | -25,1 | |
|
Net income Million USD | Released Forecast Spread | -49,0 -47,9 -2.3% | -47,3 -25,7 -83.75% | -52,2 -47,5 -10.02% | -59,8 0,21 -28006.03% | -44,9 -48,0 6.44% | -56,2 -46,0 -22.16% | -54,3 -50,3 -8.06% | -41,7 -42,8 2.62% | -19,5 -19,5 -0.05% | -22,3 | -22,6 | -22,9 | -23,3 | |
|
EPS USD | Released Forecast Spread | -0,68 -0,67 -1.65% | -0,59 -0,32 -84.08% | -0,55 -0,52 -5.91% | -0,61 -0,01 -9342.72% | -0,44 -0,49 9.92% | -0,52 -0,43 -21.45% | -0,47 -0,44 -7.29% | -0,35 -0,37 4.38% | -0,16 -0,16 0.54% | -0,18 | -0,18 | -0,18 | -0,18 | -0,23 |
| Announcement Date | 28/02/22 | 09/05/22 | 08/08/22 | 07/11/22 | 28/02/23 | 09/05/23 | 08/08/23 | 07/11/23 | 28/02/24 | - | - | - | - | - |
| Today 01:35 am | EXELIXIS, INC.: Q1 2024 Earnings Release |
| 01/05/2024 | SUMMIT THERAPEUTICS INC.: Q1 2024 Earnings Release |
| 01/05/2024 | MACROGENICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | REGENXBIO INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | DECIPHERA PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 04:30 pm | NEUROCRINE BIOSCIENCES, INC.: Q1 2024 Earnings Release |
| 02/05/2024 01:35 am | SAREPTA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 | ZENTALIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | DENALI THERAPEUTICS INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | GERON CORPORATION: Q1 2024 Earnings Release |
Past sector events for Mersana Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- MRSN Stock
- Calendar Mersana Therapeutics, Inc.
